EuroPCR 2025: Is the Future of Severe Pulmonary Embolism Interventional?

This content was sponsored by Boston Scientific.

EuroPCR is the premier global forum for advancing interventional cardiovascular medicine. At its 2025 edition, the Pulmonary Embolism (PE) Symposium offered a unique opportunity to engage with specialists from around the world focused on advancing their expertise in managing PE, a condition directly responsible for 15% of hospital deaths.¹

“We’ve managed to get STEMI mortalities down to 2%. If you don’t have shock. These are patients who don’t have shock and yet we’ve got mortalities five times as high. So there’s no question that there’s unmet need in pulmonary embolism.” – Andrew Sharp on PE mortality rates

Experts from various fields share insights on PE treatment, including:

• A focus on catheter-directed thrombolysis and ultrasound impact on clot structure.
• Discussion on real-world case studies.
• Insights from the HI-PEITHO study, a state-of-the-art randomised trial.

[Watch the full video here]

1. University College Dublin and Mater Misericordiae Hospital, Ireland
2. Professor of Vascular Biology University of Leeds, UK
3. Medical Director of the Centre for Thrombosis and Haemostasis Mainz, Germany
4. Jagiellonian University of Krakow, Poland

Reference:

1. Beers MH et al., The Merck Manual of Diagnosis and Therapy (2006) 18th edition, Whitehouse Station, NJ: Merck Research Laboratories, pp.412-22, 427, 2081-2.

The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

2025 Copyright © Boston Scientific Corporation or its affiliates. All rights reserved. PI-2219404-AA CE 2797